A widening of tiny, fluid-filled spaces in certain brain regions could be used as an imaging marker of levodopa-induced dyskinesia (LID) in people with Parkinson’s disease, a study showed. Perivascular spaces, or PVSs, were larger in Parkinson’s patients with LID — a condition in which standard Parkinson’s medications…
NeuroVigil has launched its iBrain personal brain monitor — an investigational portable device that can noninvasively record the brain’s electrical activity in people with neurological conditions — in the U.S., according to a company press release. In the second phase of the launch, NeuroVigil will use a smaller…
The first patients received doses of an oral thin-film formulation of montelukast in a clinical trial testing the treatment’s potential for Parkinson’s disease. The placebo-controlled MONTPARK trial will test how well a high dose of Montelukast VersaFilm, a proprietary formulation being developed by IntelGenx, can slow the progression…
DrTalks, a platform that aims to advance wellness and medicine by connecting people with health experts, has set the dates for its virtual meeting in November — dubbed the Parkinson’s Solutions Summit 2.0 — designed to provide insights into how to better manage and treat the progressive neurodegenerative…
Levels of two markers of intestinal inflammation — beta-defensin 2 and lactoferrin — were elevated in the stools of Parkinson’s disease patients when compared with healthy adults, and were associated with a likelihood of developing the disease, a study found. Calprotectin, a marker of tissue inflammation, wasn’t found to…
Anxiety is common among people with Parkinson’s disease and contributes to a worse life quality for patients irrespective of motor symptom severity, according to a new German study. Nearly 40% of the patients in the small study were found to have clinically relevant anxiety — and those with more…
The presence of salt or a molecular crowd may make it more likely for the alpha-synuclein protein, which forms toxic clumps in the brains of people with Parkinson’s disease, to aggregate, or build up, into droplets, according to computer simulations run by researchers in India. Understanding how alpha-synuclein behaves,…
Among people in the early stages of Parkinson’s disease, a tool called trabecular bone score, or TBS, may help detect bone loss sooner than the bone mineral density (BMD) exam that’s the current gold standard, according to researchers. Specifically, the TBS tool may work better in assessing the degradation…
The U.S. Food and Drug Administration (FDA) said it needs more information before deciding whether to approve the apomorphine infusion pump SPN-830 for the treatment of Parkinson’s disease, according to a press release from the device’s developer Supernus Pharmaceuticals. In a complete response letter (CRL) to…
People with Parkinson’s disease are nearly twice as likely to experience delirium during hospital stays as hospitalized older adults without the neurodegenerative disease, according to a study from Newcastle University. Data showed that delirium, which often goes undocumented in Parkinson’s, was reported in as many as two-thirds of…
Get regular updates to your inbox.
